The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease.

Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to heart problems in diabetes patients with chronic kidney disease.

Ozempic, the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat Type 2 diabetes, was recently OK’d to help reduce risks linked to chronic kidney disease (CKD).

Share on Pinterest The FDA approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. urbazon/Getty Images The Food and Drug Administration (FDA ...

Semaglutide reduced the risk of kidney disease worsening ... “This approval for Ozempic allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients ...